Akero Therapeutics Inc.

NASDAQ: AKRO · Real-Time Price · USD
48.54
-1.55 (-3.09%)
At close: Aug 15, 2025, 12:33 PM

Akero Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
18K 29K 260K 244K
Gross Profit
-18K -29K -260K -244K
Operating Income
-285.42M -172.87M -115.16M -100.89M
Interest Income
38.03M 24.21M 3.86M 109K
Pretax Income
-252.06M -151.76M -112.03M -100.78M
Net Income
-252.06M -151.76M -108.91M -100.74M
Selling & General & Admin
37.93M 31.07M 29.87M 19.13M
Research & Development
247.5M 141.8M 85.28M 81.76M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
285.42M 172.87M 115.16M 100.89M
Interest Expense
4.67M 3.1M 739K n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
285.42M 172.87M 115.16M 100.89M
Income Tax Expense
n/a n/a -3.12M -41K
Shares Outstanding (Basic)
67.14M 52.57M 38.98M 34.83M
Shares Outstanding (Diluted)
67.14M 52.57M 38.98M 34.83M
EPS (Basic)
-3.75 -2.89 -2.87 -2.89
EPS (Diluted)
-3.75 -2.89 -2.87 -2.89
EBITDA
-285.42M -148.63M -111.03M -100.53M
EBIT
-256.73M -148.66M -111.29M -100.78M
Depreciation & Amortization
-28.7M 29K 260K 244K